PHARMACOVIGILANCE IN CLINICAL RESEARCH: PAST, PRESENT AND FUTURE
The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Ethics committee, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. India’s growing partaking in multinational trials, this artifact explores potential areas of Indian pharmacovigilance, requiring reform and provides recommendations for building a robust safety reporting system. (1) Despite global focus on Development Safety Update Report, local regulators are not yet insistent on real-time update of a drug's cumulative safety profile. Issues like reporting requirements for generic trials, pregnancy reporting and lenient timeline for death/life-threatening events need attention. (2)
2. Brahmachari B, Fernandes M, Bhatt A. Pharmacovigilance for clinical trials in India: Current practice and areas for reform. - PubMed - NCBI [Internet]. 2016 [cited 2016 Oct 10]. Available from:
3. Clinical Research Regulation in India [Internet]. Scribd; 2016 [cited 2016 Oct 10]. Available from: https://es.scribd.com/doc/207479435/Clinical-Research-Regulation-in-India
4. MAITI RM R. Clinical trials in India. Pharmacological Research. 2007; 56(1):1-10.
5. Jayasheel BG. Carrying out clinical trials in India. [Internet]. RAJ Pharma; 2010 Jun [cited 2016 Oct 10]. Available from:
http://www.acunovalife.com/pdf/whitepapers/RAJ_Pharma%20June%202010_Jayasheel%20final.pdf. [Ref list]
6. John A. India’s attractive again for clinical trials: Quintiles CEO - Times of India [Internet]. The Times of India; 2016 [cited 2016 Oct 10]. Available from:
7. Glorious metamorphosis: compelling reasons for doing clinical research in India [Internet]. Worldcat.org; 2016 [cited 2016 Oct 10]. Available from:
8. Eleventh Five Year Plan (2007-2012) New Delhi: Oxford University Press. Social Sector: Volume II; Planning Commission, Government of India; 2008 [Ref list]
9. Law Relating to Drugs & Cosmetics [Internet]. Cdsco.nic.in; 2016 [cited 2016 Oct 10]. Available from:
10. Amended Schedule Y [Drug and Cosmetic act (2nd amendment) rules] [Internet]. New Delhi: 2005 Jan 20 [cited 2016 Oct 12]. Available from: http://www.cdsco.nic.in/html/scheduleY%20(Amended%20Version2005)%20original.htm . [Ref list]
11. ICMR, Ethical Guidelines for Biomedical Research on Human Participants [Internet]. ICMR; 2006 [cited 2016 Oct 11]. Available from:
http://www.icmr.nic.in/ethical_guidelines.pdf. [Ref list]
12. CDSCO, Good Clinical Practices for Clinical Research in India, Schedule Y (Amended Version – 2005) [Internet]. CDSCO; 2005 [cited 2016 Oct 13]. Available from:
http://cdsco.nic.in/html/GCP1.html. [Ref list]
13. Nundy S, Gulhati CM. A new colonialism?--Conducting clinical trials in India. N Engl J Med. 2005 Apr 21; 352(16):1633-6.[PubMed] [Ref list]
14. Thatte UM, Bavdeka SB. Clinical Research in India: Great expectations. J Postgrad Med. 2008; 54:318-23. [PubMed] [Ref list]
15. Ghooi RB. Trials and tribulations of clinical research teaching and training. Perspect Clin Res. 2010 Oct; 1(4):139-42. [PubMed] [Ref list]
16. Srinivasan S. A stinging indictment of India's Drug regulatory Authority. Economic and Political weekly. 2012; 47:10-3. [Ref list]
17. Pharmacovigilance programme of India. [Internet] CDSCO, Ministry of Health and Family Welfare, Government of India; 2010 Nov [cited 2016 Oct 12]. Available from:
http://www.cdsco.nic.in/pharmacovigilance_intro.htm. [Ref list]
18. Indian Pharmacopoeias Commission. [Internet]. NCC Pharmacovigilance programme of India; 2012 [cited 2016 Oct 12]. Available from:
http://www.ipc.gov.in/index1.asp?linkid=222. [Ref list]
19. Chemtech Foundation [Internet]. Pharma Biotech; 2016 [cited 2016 Oct 11]. Available from:
20. Indian Pharmacopoeia commission [Internet]. Pharmacovigilance Programme of India; 2010 [cited 2016 Oct 13]. Available from:
21. Food and Drug Administration. Guidance for Industry and Investigators: Safety Reporting Requirements for IND and BA/BE studies [Internet]. Draft guidance; 2010. [cited 2016 Oct 11]. Available from:
http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351pdf [accessed on 2010 Dec 10] [Ref list]
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Rights of Authors:
The International Journal of Drug Regulatory affairs. recognize the retention of the following:
- Patent and trademark rights and rights to any process or procedure described in the article.
- The right to photocopy or make single electronic copies of the article for their own personal use, including for their own classroom use, or for the personal use of colleagues, provided the copies are not offered for sale and are not distributed in a systematic way outside of their employing institution (e.g. via an e-mail list or public file server). Posting of an article on a secure network (not accessible to the public) within the author’s institution is permitted.
- The right, subsequent to publication, to use the article or any part thereof free of charge in a printed compilation of works of their own, such as collected writings or lecture notes.
Note: All copies, paper, electronic or other use, of the information must include an indication of the IJDRA copyright and a full citation of the journal source.
- If the article was prepared jointly with other author(s), the signing author has informed the co-author(s) of the terms of this copyright transfer and is signing on their behalf as their agent and represents that he or she is authorized to do so, then please confirm by checking the appropriate box following the signature line. The signing author shall bear the responsibility for designating the co-author(s) and must inform the IJDRA of any changes in authorship.
- If copyright is held by the employer, then the employer or an authorized representative of the employer must sign. If the author signs, it is understood that this is with the authorization of the employer and the employer’s acceptance of the terms of the transfer.
The author(s) warrant(s) that the article is the author’s original work and has not been published before. The author(s) warrant(s) that the article contains no libelous or other unlawful statements, and does not infringe on the rights of others. If excerpts from copyrighted works are included, the author(s) has (have) obtained or will obtain written permission from the copyright owners and will credit the source in the article.
Preprints: The author(s) must agree that if a prior version of this work (normally a preprint) has been posted to an electronic public server, they will not update and/or replace the prior version in order to make it identical in content to the final published version.